Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$1.60MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Arthur Kuan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 142
- Beta
- 0.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 76.05
Financials
Revenue
$1.60M+726.8%Net Income
$-56.89MEBITDA
$-55.74MFree Cash Flow
$-48.82MEPS (diluted)
$-0.64Shares Outstanding (diluted)
88.87M+33.4%Operating Expenses
$62.18MCash & Debt
$984.46MRevenue by Segment (annual)
$806.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.04M | $-161.00M | $-2.08 |
| 2024 | $1.14M | $-88.04M | $-1.41 |
| 2023 | $204.0K | $-48.61M | $-1.02 |
| 2022 | $191.0K | $-35.44M | $-0.66 |
| 2021 | $10.36M | $-12.84M | $-0.28 |
Valuation
CGONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
75+50.00%Social Signal Score
Mentions (11)
- News (RSS)seekingalpha·8h ago·Positive
CG Oncology: The Growing Bull Case Still Has An Aggressive Valuation (Rating Upgrade)
View source ↗ - News (RSS)seekingalpha·1d ago·Positive
CG Oncology: Strong Phase 3 Data Lifts Fair Value, But Leaves Limited Upside
View source ↗ - Newsschaeffersresearch.com·6d ago·Negative
2 Cancer-Drug Developers Seeing Unusual Options Volume Two cancer drug developers are seeing unusual options activity today, with Summit Therapeutics Inc (NASDAQ:SMMT) and CG Oncology Inc (NASDAQ:CGON) moving in opposite directions following major clinical and regulatory developments.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC) – Cretostimogene reduced the risk of recurrence by 68%, demonstrating a statistically significant and clinically meaningful benefit with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy
View source ↗ - Newsseekingalpha.com·26d ago·Positive
…ring Therapy CG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene, offering a clean tolerability profile and randomized Phase 3 data. CGON's $1B+ cash position funds operations through 2029, with recent ATM activity signaling strong institutional interest rather than funding desperation. PIVOT-006 trial and BLA completion are imminent catalysts; positive results could unlock significant intermediate-risk NMIBC market potential.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
CG Oncology to Present at Upcoming Investor Conferences in September DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
View source ↗ - News (RSS)investing·95d ago·Neutral
CG Oncology stock hits all-time high of 79.5 USD
View source ↗ - Newsseekingalpha.com·101d ago·Positive
CG Oncology: Circling Back After Huge Rally CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
View source ↗
Earnings
Fri, Feb 26(in 3 months)
Consensus estimate $-0.68 per share
Typical surprise -6.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 6$-0.64 vs $-0.83beat
- Thu, Aug 6$-0.90 vs $-0.66miss
- Fri, May 8$-0.71 vs $-0.58miss
- Fri, Feb 27$-0.51 vs $-0.61beat
- Fri, Nov 14$-0.57 vs $-0.56miss
- Fri, Aug 8$-0.54 vs $-0.49miss
Estimates and results for CGON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CGON officers and directors.
- Bought
- $77.5m
- Sold
- $7.3m
4 trades
25 trades
- Kuan Arthurbought
- Kalofonos Isabelbought
- Post Leonard Esold
- Post Leonard Esold
- Post Leonard Esold
- Post Leonard Esold
- Post Leonard Esold
- Post Leonard Esold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CGON.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
